| Also known as |
TNFR:Fc |
| Blood pressure |
No significant effect |
| Chemical name |
Etanercept |
| Dosage (medical) |
Typically 50 mg once weekly via subcutaneous injection for adults |
| Dosage (sports) |
Not applicable |
| Effects |
Reduction of inflammation and immune response modification |
| Formula |
C2224H3475N621O701S13 |
| Half-life |
Approximately 102 hours |
| Hepatotoxicity |
Low |
| Lab Test |
Monitoring of blood counts and liver enzymes |
| Main action |
TNF inhibitor |
| Raw Material |
Etanercept |
| Side effects |
Infections, injection site reactions, allergic reactions, heart failure, demyelinating disease |
| Storage conditions |
Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F) |
| Substance class |
Biopharmaceutical, fusion protein |
| Trade name |
Enbrel |
| Use in sports |
Not typically used in sports |
| Water Retention |
Low |
| Manufacturer |
Pfizer |
| Packing |
4 vials (25mg) |
